99% Rapastinel 117928-94-6

Rapastinel More Info

Rapastinel, identified by the chemical registry number 117928-94-6, emerged from extensive research into modulating the glutamatergic system, specifically the N-methyl-D-aspartate (NMDA) receptor. Unlike traditional agents that directly block or overstimulate this receptor, Rapastinel was developed as a novel partial agonist. It functions by selectively binding to the glycine site on the NMDA receptor, thereby modulating its activity in a more nuanced manner. This compound was initially investigated for its potential to produce rapid-onset and sustained effects on synaptic plasticity, which is the foundation of learning, memory, and mood regulation. Its development represented a significant shift in therapeutic strategy, aiming to provide efficacy with a potentially improved tolerability profile compared to existing options.

Intended Use and Applications

The primary application area for Rapastinel was in the field of neurological health, specifically as a potential adjunctive therapy for Major Depressive Disorder (MDD). Preclinical and clinical studies focused on its ability to produce rapid antidepressant effects, sometimes within hours or days, as opposed to the weeks typically required for conventional antidepressants. Its mechanism of action, which involves enhancing communication between neurons and promoting the growth of new synaptic connections, targeted the core pathophysiology of depression rather than just its symptoms. This positioned it as a potential breakthrough for treatment-resistant depression and for use in acute settings where a rapid clinical response is critical.

Target Market and Commercial Landscape

The intended application market for Rapastinel was the global central nervous system (CNS) therapeutics market, with a direct focus on the multi-billion dollar antidepressant sector. Its unique value proposition of rapid efficacy targeted a significant unmet medical need, particularly for the sizable patient population that does not respond adequately to first-line treatments like SSRIs and SNRIs. The commercial strategy likely involved positioning it as a specialty pharmaceutical product administered in controlled clinical settings. Despite its promising profile and initial positive clinical data, it is important to note that further development of Rapastinel for this major indication was discontinued following the outcomes of later-stage clinical trials, which did not meet their primary efficacy endpoints.

Important Considerations

Critical considerations for this compound extend across the research and potential use spectrum. From a clinical research perspective, the discontinuation of its major development program highlights the inherent complexities and risks in developing novel neurological agents. For any future research, careful attention must be paid to trial design, patient selection, and endpoint measurement. Regarding its pharmacological profile, while it was designed for a specific receptor target, the broader effects of modulating the glutamatergic system are complex and require thorough investigation to fully understand all downstream interactions. All handling and use in a research context must adhere to strict safety protocols, including the use of appropriate personal protective equipment (PPE) and engineering controls, as the full material characteristics and handling hazards for non-pharmaceutical grade material must be assessed via a comprehensive Safety Data Sheet (SDS).

Package Image

FAQ

Q1. Can I get a free sample?

We can send you a samll free sample, and you only need to pay for the shipping cost.

Q2. What is the HyperChem payment term?

T/T in advance
LC at sight
DP at sight

Bank transfer

PayPal

Bitcoin...

Q3. What is HyperChem shipment policy?

Our policy is to strive for the quickest shipment time possible.

For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.

Q4. What is HyperChem shipment term?

By Express  
FedEx  UPS  DHL  EMS                               
Fast: 3-7 days around, high cost, door to door service

By Air                                        
Suitable for more than 50kg 
Fast: 3-7 days, hight cost, port to port, professional broker needed 

By Sea
Suitable for more than 500kg      
Fast: 7-45 days, low cost, port to port, professional broker needed 

We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

Q5. What HyperChem will provide after shipment?

For sample orders: 
After shipment is done, an timely email including:

1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice

For commercial orders
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.

Company Profile

Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to cater to the requirements of our diverse range of clients.

Among them, our key client industrial sectors around the global are:

Pharmaceuticals
Nutrition Ingredients/ Dietary supplements
Cosmetic Ingredients
Food Ingredients
Veterinary API
Agriculture fertilizer
Custom Synthesis lab supply

HyperChem provides to its wonderful and honorable clients comprehensive purchasing and distribution services which ensure that we are delivering the right generic, raw, or customized product, make sure that we are delivering it at the right time, ensure that it is delivered in the specified amount, and in the right kind of packaging to clients and customers of all types of industries irrespective of their size of operation.